标题
Immunomodulation by targeted anticancer agents
作者
关键词
BRAF, CD8, cytotoxic T lymphocytes, CDK4/CDK6, CGAS signaling, DNA damage response, EGFR, immune checkpoint blockers, immunogenic cell death, KRAS, TGF-β, T, REG, cells
出版物
CANCER CELL
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2020-12-18
DOI
10.1016/j.ccell.2020.11.009
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells
- (2020) Sanjay Varikuti et al. BRITISH JOURNAL OF CANCER
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- (2020) Laura M Spring et al. LANCET
- EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas
- (2020) Yasuyuki Otsuka et al. MOLECULAR IMMUNOLOGY
- Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice
- (2020) Lucia Moreno-Lama et al. ONCOGENE
- Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth
- (2020) Yan Li et al. Cell Reports
- Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC
- (2020) Annunziata Nigro et al. Frontiers in Immunology
- Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
- (2020) Qiaohong Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
- (2020) Marcus Ruscetti et al. CELL
- Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer
- (2020) James R Whittle et al. CLINICAL CANCER RESEARCH
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
- (2020) Keisuke Yamamoto et al. NATURE
- Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
- (2020) Chuanhui Han et al. NATURE IMMUNOLOGY
- Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
- (2020) Daniel Baumann et al. Nature Communications
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
- (2020) Lauren E. Stopfer et al. Nature Communications
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
- (2020) Lorenzo Galluzzi et al. Journal for ImmunoTherapy of Cancer
- ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
- (2020) Hailong Sheng et al. Journal for ImmunoTherapy of Cancer
- Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer
- (2020) Qilai Long et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
- (2020) Dong Wang et al. CANCER LETTERS
- ATR inhibition potentiates ionizing radiation‐induced interferon response via cytosolic nucleic acid‐sensing pathways
- (2020) Xu Feng et al. EMBO JOURNAL
- CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer
- (2020) Jian Wang et al. Journal of Hematology & Oncology
- Inhibition of Aurora-A Promotes CD8+ T-Cell Infiltration by Mediating IL10 Production in Cancer Cells
- (2020) Jing Han et al. MOLECULAR CANCER RESEARCH
- Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
- (2020) Takahiro Yamazaki et al. NATURE IMMUNOLOGY
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
- (2020) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
- (2020) Aitziber Buqué et al. Nature Communications
- Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment
- (2020) Weiwei Shan et al. Cell Reports
- Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
- (2020) Jessica L.F. Teh et al. Cancer Immunology Research
- AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
- (2020) Ilyas Sahin et al. Cell Death Discovery
- The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276
- (2020) Ruidong Li et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
- (2020) Jin Huang et al. GUT
- Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses
- (2020) Jie Chen et al. Cell Reports
- PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
- (2020) Chiho Kim et al. eLife
- PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax
- (2020) Neus Serrat et al. Blood Advances
- Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients
- (2019) Pauline L de Goeje et al. CLINICAL CANCER RESEARCH
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
- (2019) E. Dodagatta-Marri et al. Journal for ImmunoTherapy of Cancer
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
- (2019) Heidi M. Haikala et al. Nature Communications
- Modulation of immune checkpoint molecule expression in mantle cell lymphoma
- (2019) Bonnie K. Harrington et al. LEUKEMIA & LYMPHOMA
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: implications for combination therapies
- (2019) Yijun Jia et al. INTERNATIONAL JOURNAL OF CANCER
- ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
- (2019) Magnus T. Dillon et al. CLINICAL CANCER RESEARCH
- Commensal Microbiota Promote Lung Cancer Development via γδ T Cells
- (2019) Chengcheng Jin et al. CELL
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
- (2019) Meghan Travers et al. CANCER RESEARCH
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
- (2019) Hyejin Choi et al. Cell Reports
- Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
- (2019) Chiara Napoletano et al. Journal of Clinical Medicine
- Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma
- (2019) Thijs W.H. Flinsenberg et al. HAEMATOLOGICA
- Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
- (2019) Nithya Sivaram et al. JOURNAL OF CLINICAL INVESTIGATION
- Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
- (2019) Anna M. Paczulla et al. NATURE
- Crizotinib-induced immunogenic cell death in non-small cell lung cancer
- (2019) Peng Liu et al. Nature Communications
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer
- (2019) Mei Hua Jin et al. Cancer Research and Treatment
- Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
- (2019) Silvia C. Formenti et al. Journal for ImmunoTherapy of Cancer
- Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling
- (2019) Koen A. Marijt et al. Journal for ImmunoTherapy of Cancer
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
- (2019) Nina Mallmann-Gottschalk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
- (2019) Alexander Thiem et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes
- (2019) Tom Hofland et al. JOURNAL OF IMMUNOLOGY
- Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression
- (2019) Sanjay Chandrasekaran et al. MOLECULAR CANCER RESEARCH
- Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2‐deficient cancer cells
- (2019) Pepijn M. Schoonen et al. Molecular Oncology
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles
- (2019) Claire Vanpouille-Box et al. NATURE REVIEWS DRUG DISCOVERY
- Apoptotic caspases cut down the immunogenicity of radiation
- (2019) Aitziber Buqué et al. OncoImmunology
- Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy
- (2019) Deepak Mittal et al. OncoImmunology
- Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients
- (2019) Maria Esperanza Rodriguez-Ruiz et al. OncoImmunology
- Cellular Senescence: Defining a Path Forward
- (2019) Vassilis Gorgoulis et al. CELL
- Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
- (2019) Sara A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
- (2019) Iva Truxova et al. HAEMATOLOGICA
- Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
- (2019) Atsushi Tanaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Imatinib and the long tail of targeted drug development
- (2019) Benjamin G. Carlisle et al. Nature Reviews Clinical Oncology
- Synthetic lethality as an engine for cancer drug target discovery
- (2019) Alan Huang et al. NATURE REVIEWS DRUG DISCOVERY
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
- (2019) Qingfei Wang et al. Nature Communications
- Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation
- (2019) Atiqur Rahman et al. eLife
- MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
- (2019) Douglas D. Fang et al. Journal for ImmunoTherapy of Cancer
- Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients
- (2019) Lenka Kasikova et al. Journal for ImmunoTherapy of Cancer
- CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
- (2019) Hua Zhang et al. CANCER CELL
- A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
- (2019) Lydia Bellmann et al. INTERNATIONAL JOURNAL OF CANCER
- Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
- (2019) Maria Esperanza Rodriguez-Ruiz et al. NATURE IMMUNOLOGY
- Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
- (2019) Dan A. Erkes et al. Cancer Discovery
- Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3
- (2018) Bingxin Zheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- Cytosolic DNA Sensing in Organismal Tumor Control
- (2018) Claire Vanpouille-Box et al. CANCER CELL
- DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway
- (2018) Yoshinobu Saito et al. CELL DEATH AND DIFFERENTIATION
- Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment
- (2018) Ganjun Yu et al. Cellular & Molecular Immunology
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
- (2018) Silvia C. Formenti et al. CLINICAL CANCER RESEARCH
- BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
- (2018) Martina Sanlorenzo et al. CLINICAL CANCER RESEARCH
- Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
- (2018) Dewan Md Sakib Hossain et al. JOURNAL OF CLINICAL INVESTIGATION
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
- (2018) Qi Lai et al. ONCOGENE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
- (2018) Rajani Ravi et al. Nature Communications
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
- (2018) David Wang et al. Cell Reports
- NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
- (2018) Agnieszka Witalisz-Siepracka et al. Cancer Immunology Research
- Macrophages and CD8 + T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors
- (2018) Jennifer Q. Zhang et al. Cancer Immunology Research
- T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response
- (2018) Laura Aragoneses-Fenoll et al. Frontiers in Immunology
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice
- (2018) Jae-Hyeog Choi et al. OncoImmunology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation
- (2018) Frank P. Vendetti et al. JOURNAL OF CLINICAL INVESTIGATION
- Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
- (2018) Gillian Dunphy et al. MOLECULAR CELL
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer
- (2018) Toshihiro Misumi et al. PLoS One
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies
- (2018) Karl R. VanDerMeid et al. Cancer Immunology Research
- Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF-β Inhibitor Sequencing in Melanoma
- (2018) Fei Zhao et al. Cancer Immunology Research
- A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
- (2018) Patrick H. Lizotte et al. Cancer Immunology Research
- Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
- (2018) Seong-Ho Kang et al. OncoImmunology
- Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
- (2018) Tiziana Triulzi et al. BRITISH JOURNAL OF CANCER
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
- (2018) Ryota Tamura et al. CANCER SCIENCE
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages
- (2018) Shicheng Su et al. CELL
- PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
- (2018) Shuai Dong et al. JOURNAL OF CLINICAL INVESTIGATION
- PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
- (2018) Bola S. Hanna et al. LEUKEMIA
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
- (2018) Meili Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
- (2018) Ankur Chakravarthy et al. Nature Communications
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
- (2018) Kathleen E. Fenerty et al. Journal for ImmunoTherapy of Cancer
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages
- (2017) Francesca Bellora et al. JOURNAL OF IMMUNOLOGY
- Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
- (2017) K Kondo et al. LEUKEMIA
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency
- (2017) Evangelos Giampazolias et al. NATURE CELL BIOLOGY
- Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
- (2017) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- COX2/mPGES1/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
- (2017) Victor Prima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
- (2017) Sathana Dushyanthen et al. Nature Communications
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer
- (2017) Dai Liu et al. OncoImmunology
- Trial watch: Immune checkpoint blockers for cancer therapy
- (2017) Claire Vanpouille-Box et al. OncoImmunology
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
- (2017) Sheila López-Cobo et al. OncoImmunology
- The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
- (2017) Edmund Poon et al. Journal for ImmunoTherapy of Cancer
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
- (2016) S. Vasu et al. BLOOD
- Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis
- (2016) Michael J. Allegrezza et al. CANCER RESEARCH
- Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8 + T Cells
- (2016) Deepak Mittal et al. CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors
- (2016) M. J. Allegrezza et al. CANCER RESEARCH
- PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
- (2016) Jiqing Sai et al. CLINICAL CANCER RESEARCH
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
- (2016) Adrian M. Seifert et al. CLINICAL CANCER RESEARCH
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment
- (2016) Yan Cui et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- Immunological off-target effects of imatinib
- (2016) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
- (2016) Per Hydbring et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
- (2016) Stefanie N. Linch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Macrophage PI3K Drives Pancreatic Ductal Adenocarcinoma Progression
- (2016) M. M. Kaneda et al. Cancer Discovery
- EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
- (2016) Abhilash Venugopalan et al. Oncotarget
- Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance
- (2016) Sarah Sharon Gabriel et al. Frontiers in Immunology
- NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
- (2016) Sylvie Rusakiewicz et al. OncoImmunology
- EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
- (2015) Kailong Lin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Anti-CD20 Therapy Acts via Fc RIIIA to Diminish Responsiveness of Human Natural Killer Cells
- (2015) C. Capuano et al. CANCER RESEARCH
- TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
- (2015) Claire Vanpouille-Box et al. CANCER RESEARCH
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
- (2015) David Roulois et al. CELL
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
- (2015) Yun Shi et al. JOURNAL OF IMMUNOLOGY
- Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype
- (2015) Meng Xu et al. JOURNAL OF IMMUNOLOGY
- Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
- (2015) Anna E. Vilgelm et al. JNCI-Journal of the National Cancer Institute
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
- (2015) Ende Zhao et al. NATURE IMMUNOLOGY
- Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
- (2015) Riki Okita et al. PLoS One
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion
- (2015) Wei-Ta Chen et al. eLife
- Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment
- (2015) Anna E. Vilgelm et al. JNCI-Journal of the National Cancer Institute
- Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
- (2015) L. Wang et al. Cancer Immunology Research
- CD4 + T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8 + T-cell Targeting of HER2/ neu –Expressing Cancers
- (2015) Jashodeep Datta et al. Cancer Immunology Research
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
- (2015) Jitka Fucikova et al. Frontiers in Immunology
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
- (2015) Jing Li et al. Journal for ImmunoTherapy of Cancer
- Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
- (2015) Agnes S. Klar et al. PLoS One
- Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy
- (2014) A. B. van der Waart et al. BLOOD
- Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
- (2014) A. E. Vilgelm et al. CANCER RESEARCH
- Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFN
- (2014) P.-C. Ho et al. CANCER RESEARCH
- Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
- (2014) L. Ferrari de Andrade et al. CANCER RESEARCH
- Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
- (2014) J. G. Crompton et al. CANCER RESEARCH
- Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production
- (2014) Michael J. White et al. CELL
- Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA
- (2014) Anthony Rongvaux et al. CELL
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
- (2013) A. C. West et al. CANCER RESEARCH
- Non-Cell-Autonomous Tumor Suppression by p53
- (2013) Amaia Lujambio et al. CELL
- Effective Anti-Neu-Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells
- (2013) E. D. Mortenson et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- IgAEGFR antibodies mediate tumour killingin vivo
- (2013) Peter Boross et al. EMBO Molecular Medicine
- Deregulation of Apoptotic Factors Bcl-xL and Bax Confers Apoptotic Resistance to Myeloid-derived Suppressor Cells and Contributes to Their Persistence in Cancer
- (2013) Xiaolin Hu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells
- (2013) Alexandre Iannello et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
- (2013) Sisi He et al. Journal of Translational Medicine
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
- (2012) Andrea Cavazzoni et al. Molecular Cancer
- IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR
- (2011) M. P. Roberti et al. BREAST CANCER RESEARCH AND TREATMENT
- Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
- (2011) S. Textor et al. CANCER RESEARCH
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
- (2011) J. Pander et al. CLINICAL CANCER RESEARCH
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
- (2011) Steve C. Lee et al. IMMUNOLOGIC RESEARCH
- Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
- (2011) Greta Garrido et al. JOURNAL OF IMMUNOLOGY
- IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- Production
- (2011) A. C. Jaime-Ramirez et al. JOURNAL OF IMMUNOLOGY
- EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells
- (2011) Hyunsu Kim et al. JOURNAL OF IMMUNOTHERAPY
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
- (2011) Tae-Won Kang et al. NATURE
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy
- (2011) Qian Huang et al. NATURE MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural Killer Cell IFN- Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
- (2009) C. Menard et al. CANCER RESEARCH
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- mTOR regulates memory CD8 T-cell differentiation
- (2009) Koichi Araki et al. NATURE
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- (2008) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma
- (2008) Atsushi Natsume et al. INTERNATIONAL JOURNAL OF CANCER
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced T-Cell Responses to Glioma Cells Coated With the Anti-EGF Receptor Antibody and Targeted to Activating Fc??Rs on Human Dendritic Cells
- (2008) Devi Banerjee et al. JOURNAL OF IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started